A Clinical Safety and Efficacy Study of Mebendazole on GI Cancer or Cancer of Unknown Origin.

Inclusion Criteria

• •1. At least 18 years of age.
• •2. Histologically confirmed diagnosis of squamous cell cancer or adenocarcinoma, including primary cancer of the liver, of the gastrointestinal tract or cancer of unknown origin.
• •3. Measurable disease according to RECIST 1.1.
• •4. Defined time to tumour progression on the standard/experimental treatment preceding the trial treatment.
• •5. Locally advanced or metastatic disease not amenable to standard treatment, i.e. progress on standard therapy or observed/expected intolerance to standard therapy.
• •6. \- (removed via Amendment 1)
• •7. Pharmacological treatment attempt considered reasonable.
• •8. Females of childbearing potential should use adequate contraception throughout the study;
• •1. Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal)
• •2. Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable or implantable)
• •3. Intrauterine device (IUD)
• •4. Intrauterine hormone-releasing system (IUS)
• •5. Bilateral tubal occlusion
• •6. Vasectomized partner
• •7. Sexual abstinence
• •9. Signed informed consent.